moxifloxacin has been researched along with exenatide in 2 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (exenatide) | Trials (exenatide) | Recent Studies (post-2010) (exenatide) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 22 | 0 | 16 |
| 3,157 | 552 | 1,690 | 2,806 | 383 | 2,016 |
| Protein | Taxonomy | moxifloxacin (IC50) | exenatide (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Rattus norvegicus (Norway rat) | 0.0001 | |
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0023 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cirincione, B; Darpö, B; Han, J; Huang, W; MacConell, L; Malloy, J; Mitchell, M; Porter, L; Sager, P; Schulteis, C; Shen, L | 1 |
1 review(s) available for moxifloxacin and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and exenatide
| Article | Year |
|---|---|
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Exenatide; Female; Fluoroquinolones; Heart Rate; Humans; Hypoglycemic Agents; Infusions, Intravenous; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Peptides; Quinolines; Venoms | 2013 |